At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
Small Molecule Agent (PF-868554) +1 moredrug
Likely dose
Small Molecule Agent (PF-868554) 700mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Non- Randomized, Open Label, Sequential Group, Multicenter Study To Evaluate The Antiviral Activity Of Multiple Doses Of A Small Molecule Direct Antiviral Agent In Chronically Infected Hepatitis C Subjects.
In Brief
A Phase 1 clinical trial evaluating Small Molecule Agent (PF-868554) for Hepatitis, Chronic and Hepatitis C Virus. Completed, enrolled 20 participants across 1 site.
Detailed Summary
Phase 1 study in HVC (Hepatitis C Virus) infected subjects to determine pharmacokinetics, safety and efficacy in subjects with no or inadequate response to prior treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis, Chronic, Hepatitis C Virus
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2008
First PostedMay 2008
Primary CompletionDec 2008
TodayJul 2026
First PostedMay 5, 2008
Enrollment StartApr 1, 2008
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 18.2 years ago
Interventions
Small Molecule Agent (PF-868554)drug
Study drug will be administered 700mg BID in the fed state for three days.
Small Molecule Agent (PF-868554)drug
Study drug will be given 450mg BID for a duration of 10 days.